Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis

Clinical Drug Investigation

Volumn 12, Issue 5, 1996, Pages 244-250

  Nakagawa, H ^a   Etoh, T ^a   Yokota, Y ^b   Ikeda, F ^b   Hatano, K ^b   Teratani, N ^b   Shimomura, K ^b   Mine, Y ^b   Amaya, T ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MICONAZOLE; PYRROLNITRIN; TACROLIMUS;

ANTIFUNGAL ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS SPORE; GRAFT REJECTION; HUMAN; MALASSEZIA FURFUR; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0029852215     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199612050-00003     Document Type: Article

References (20)

1. Hatanaka H, Iwami M, Kino T, et al. FR-900520 and FR-900523: novel immunosuppressants isolated from Streptomyces. I. Taxonomy of the producing strain. J Antibiotics 1988; 41: 1586-91
2. Izumi S, Okuhara M. FK506 and kifunensin: new immunomodulators of microbial origin. Protein Nuc Acid Enzyme 1993; 38: 1800-12
3. Thomson AW, Starzl TE. FK506 and autoimmune disease: perspectives and prospects. Autoimmunity 1992; 122: 303-13
4. Abu-Elmagd K, Thiel DV. FK506: a new therapeutic agent for severe psoriasis. Transplant Proc 1991; 23: 3322-4
5. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883
6. Mori A, Suko M, Nishizaki Y, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994; 104 Suppl.: 32-5
7. Roberts SOB. Pityrosporum orbiculare: incidence and distribution on clinically normal skin. Brit J Dermatol 1969; 81: 264-9
8. Faergemann J, Aly R, Maibach HI. Quantitative variations in distribution of Pityrosporum orbiculare on clinically normal skin. Acta Derm Venereol (Stockh) 1983; 63: 346-8
9. Back O, Faergemann J, Hornquist R. Pityrosporum folliculitis: a common skin disease of the young and middle aged. J Am Acad Dermatol 1985; 12: 56-61
10. Rosenberg EW, Belew PW. Improvement of psoriasis of the scalp with ketoconazole. Arch Dermatol 1982; 118: 370-1
11. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984; 111: 235-42
12. Waersted A, Hjorth N. Pityrosporum orbiculare: a pathogenetic factor in atopic dermatitis of the face, scalp and neck? Acta Derm Venereol 114 (Stockh) 1985; 114: 146-8
13. Rokugo M, Tagami H, Usuba Y, et al. Contact sensitivity to Pityrosporum ovale in patients with atopic dermatitis. Arch Dermatol 1990; 126: 627-32
14. Kieffer M, Bergbrant I-M, Faergemann J. Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrhoeic dermatitis. J Am Acad Dermatol 1990; 22: 739-42
15. Wessels MW, Doekes G, Van Ieperen-Van Dink AG, et al. IgE antibodies to Pityrosporum ovale in atopic dermatitis. Br J Dermatol 1991; 125: 227-32
16. Nordvall SL, Lindgren L, Johansson SGO, et al. IgE antibodies to Pityrosporum orbiculare and Staphylococcus aureus in patients with high serum total IgE. Clin Exp Allergy 1992; 22: 756-61
17. Uchiyama K, Yamaguchi H. Malassezia furfur: lipophilic yeast like organism causing pityriasis versicolor. Clin Microbiol 1988; 15: 625-32
18. Madelene CYH, Henderson CL, Baker DC, et al. Correlation of Pityrosporum ovale density with clinical severity of seborrhoeic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23: 82-6
19. Clemmenth OJ, Hjorth N. Treatment of dermatitis of the head and neck with ketoconazole in patients with type I sensitivity to Pityrosporum orbiculare. Semin Dermatol 1983; 2: 26-9
20. Kawashima M, Nakagawa H, Otsuki M, et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet, 1996. In press